Absorica web site link page
Generic products of Accutane® are not interchangeable with ABSORICA®,1
Due to its high lipophilicity, oral absorption of isotretinoin is enhanced when given with a high-fat
meal. ABSORICA is bioequivalent to Accutane® (isotretinoin) capsule when both drugs are taken with
a high-fat meal. ABSORICA is more bioavailable than Accutane® (isotretinoin) capsules when both
drugs are taken fasted; the AUC0-t of ABSORICA is approximately 83% greater than that of Accutane®.
ABSORICA is therefore not interchangeable with generic products of Accutane®.1
IMPORTANT INFORMATION FOR ABSORICA
INDICATIONS AND USAGE
ABSORICA is a retinoid indicated for the treatment of severe recalcitrant nodular acne in patients
12 years of age and older. Nodules are inflammatory lesions with a diameter of 5 mm or greater.
The nodules may become suppurative or hemorrhagic. “Severe,” by definition, means “many” as
opposed to “few or several” nodules. Because of significant adverse reactions associated with its use,
ABSORICA should be reserved for patients with multiple severe nodular acne who are unresponsive
to conventional therapy, including systemic antibiotics. In addition, ABSORICA is indicated only for
those female patients who are not pregnant, because ABSORICA can cause severe birth defects.
Limitations of Use:
A single course of therapy for 15 to 20 weeks has been shown to result in
complete and prolonged remission of disease in many patients. If a second course of therapy is
needed, it should not be initiated until at least 8 weeks after completion of the first course, because
experience with isotretinoin has shown that patients may continue to improve following treatment
with isotretinoin. The optimal interval before retreatment has not been defined for patients who have
not completed skeletal growth. ABSORICA is available only through the iPLEDGE™ program, in which
prescribers, patients, pharmacies, and distributors must enroll.
IMPORTANT SAFETY INFORMATION
Pregnancy Category X
• ABSORICA must not be used by female patients who are or may become pregnant.
• There is an extremely high risk that severe birth defects will result if pregnancy occurs
while taking ABSORICA
in any amount, even for short periods of time.
• Potentially any fetus exposed during pregnancy can be affected.
• There are no accurate means of determining whether an exposed fetus has been affected.
• Birth defects which have been documented following isotretinoin exposure include abnormalities
of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and
parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been
reported. There is an increased risk of spontaneous abortion and premature births have
• Documented external abnormalities include: skull abnormality; ear abnormalities
(including anotia, micropinna, small or absent external auditory canals); eye abnormalities
(including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities
include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation,
hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland
abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain
abnormalities previously noted.
• If pregnancy does occur during the treatment of a female patient who is taking ABSORICA,
ABSORICA must be discontinued immediately and she should be referred to an Obstetrician-Gyne
cologist experienced in reproductive toxicity for further evaluation and counseling.
Special Prescribing Requirements
• Because of the risk of teratogenicity and to minimize fetal exposure, ABSORICA is available only
through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called
iPLEDGE™. Under the ABSORICA REMS, prescribers, patients, pharmacies, and distributors must
enroll and be registered in the program.
SUMMARY OF RISK INFORMATION FOR ABSORICA
Major congenital malformations, spontaneous abortions, and premature births have
been documented following pregnancy exposure to isotretinoin in any amount and even for short
• Hypersensitivity (Anaphylactic and Other Allergic Reactions):
ABSORICA is contraindicated in
patients hypersensitive to ABSORICA or its components, or Vitamin A.
WARNINGS AND PRECAUTIONS
Major congenital malformations, spontaneous abortions, and premature births have
been documented following pregnancy exposure to isotretinoin.
• Patients must be informed not to donate blood during isotretinoin therapy and for 1 month
following discontinuation because the blood may be given to a pregnant female whose fetus
must not be exposed to isotretinoin.
• Unacceptable Contraception:
Micro-dosed progesterone preparations are not an acceptable
method of contraception during ABSORICA therapy.
• Psychiatric Disorders:
Isotretinoin may cause depression, psychosis and, rarely, suicidal ideation,
suicide attempts, suicide, and aggressive and/or violent behaviors. No mechanism of action has been
established for these reactions. Prescribers should be alert to the warning signs of psychiatric
disorders to guide patients to receive the help they need. Therefore, prior to initiation of ABSORICA
therapy, patients and family members should be asked about any history of psychiatric disorder,
and at each visit during therapy patients should be assessed for symptoms of depression, mood
disturbance, psychosis, or aggression to determine if further evaluation may be necessary.
• Pseudotumor Cerebri:
Isotretinoin use has been associated with cases of pseudotumor
cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines.
Concomitant treatment with tetracyclines should therefore be avoided. Early signs and symptoms
of pseudotumor cerebri include papilledema, headache, nausea and vomiting, and visual
• Serious Skin Reactions:
There have been post-marketing reports of erythema multiforme and
severe skin reactions [e.g., Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)]
associated with isotretinoin use. These reactions may be serious and result in death.
• Acute pancreatitis, rarely fatal hemorrhagic pancreatitis, in patients with either elevated or
normal serum triglyceride levels.
• Lipid Abnormalities:
Elevations of serum triglycerides in excess of 800 mg/dL have been reported
in patients treated with isotretinoin. Some patients taking isotretinoin have developed a decrease in
high-density lipoproteins (HDL), and an increase in cholesterol levels has been reported in some
• Hearing Impairment:
Impaired hearing has been reported in patients taking isotretinoin; in some
cases, the hearing impairment has been reported to persist after therapy has been discontinued.
• Inflammatory Bowel Disease:
Isotretinoin has been associated with inflammatory bowel disease
(including regional ileitis) in patients without a prior history of intestinal disorders. In some instances,
symptoms have been reported to persist after isotretinoin treatment has been stopped.
• Bone Mineral Density Changes:
Isotretinoin may have a negative effect on bone mineral density
(BMD) in some patients. Therefore, physicians should use caution when prescribing ABSORICA to
patients with a history of childhood osteoporosis conditions, osteomalacia, or other disorders of
• Skeletal Abnormalities:
Back pain, arthralgias (in two trials of pediatric patients, back pain and
arthralgias occurred in 29% and 22% of patients, respectively, including severe back pain and
arthralgias in 13.5% and 7.6%, respectively), premature epiphyseal closure.
• Ocular Abnormalities:
Visual problems should be carefully monitored. Decreased night vision has
been reported during isotretinoin therapy and in some instances the event has persisted after
therapy was discontinued. Corneal opacities and dry eye have also been reported.
• Blood lipid determinations
should be performed before ABSORICA is given and then at intervals
until the lipid response to ABSORICA is established, which usually occurs within 4 weeks. Especially
careful consideration must be given to risk/benefit for patients who may be at high risk of
triglyceridemia during ABSORICA therapy (patients with diabetes, obesity, increased alcohol intake,
lipid metabolism disorder or familial history of lipid metabolism disorder).
Since elevations of liver enzymes have been observed during clinical trials, and
hepatitis has been reported in patients on isotretinoin, pretreatment and follow-up liver function
tests should be performed at weekly or biweekly intervals until the response to ABSORICA has been
• Glucose control problems and elevated CPK levels, including rare cases of rhabdomyolysis.
• Most common adverse reactions (incidence ≥5%) are: lip dry, dry skin, back pain, dry eye, arthralgia,
epistaxis, headache, nasopharyngitis, chapped lips, dermatitis, blood creatine kinase increased,
cheilitis, musculoskeletal discomfort, upper respiratory tract infection, visual acuity reduced.
ABSORICA [prescribing information]. Jacksonville, FL: Ranbaxy Laboratories Inc;
ABSORICA is a registered trademark of Ranbaxy Laboratories Limited.
All other trademarks are property of their respective owners.
Potential Effect of a Low-Fat, Vegan Diet on Medication Costs in Type 2 Diabetes Diabetes treatment typical y involves the use of several pharmaceutical agents. Often, one, two, or more drugs are required for blood glucose control, along with additional agents to reduce blood cholesterol and blood pressure. While drug treatments are often necessary and can be lifesaving, their use ent
Therapeutx™, the makers of Maori Miracle®, researches & develops evidence-based remedies for the safe, effective treatment of human disorders, disease prevention and the maintenance of good health. Maori Miracle® is a unique and superior arthritis formula, designed to treat arthritic symptoms, reduce inflammation, relieve pain, rebuild worn cartilage and improve joint & muscle functio